Oncopeptides AB Working Capital to Net Assets Ratio
Oncopeptides AB working capital to net assets ratio. Oncopeptides AB (ONCO) has a Working Capital to Net Assets ratio of -123.4% as of December 2025. Working capital of Skr72.66 Million (current assets of Skr117.16 Million minus current liabilities of Skr44.50 Million) is measured against net assets of Skr-58.89 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ONCO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Oncopeptides AB (2014–2025)
Working capital to net assets ratio of Oncopeptides AB from 2014 to 2025. This chart shows how Oncopeptides AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at -123.4%, reflecting working capital of Skr72.66 Million against net assets of Skr-58.89 Million SEK. See ONCO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Oncopeptides AB Working Capital to Net Assets Ratio by Year (2014–2025)
Oncopeptides AB working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Oncopeptides AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Oncopeptides AB's balance sheet.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -123.4% | Skr72.66 Million | Skr-58.89 Million | Skr117.16 Million | Skr44.50 Million | ▼ -428.7 pp |
| 2024 | 305.3% | Skr165.73 Million | Skr54.28 Million | Skr217.08 Million | Skr51.35 Million | ▲ +27.1 pp |
| 2023 | 278.2% | Skr157.97 Million | Skr56.78 Million | Skr202.90 Million | Skr44.93 Million | ▲ +183.6 pp |
| 2022 | 94.6% | Skr278.36 Million | Skr294.29 Million | Skr364.03 Million | Skr85.67 Million | ▲ +5.9 pp |
| 2021 | 88.7% | Skr187.08 Million | Skr210.87 Million | Skr412.37 Million | Skr225.29 Million | ▼ -5.0 pp |
| 2020 | 93.7% | Skr540.40 Million | Skr576.90 Million | Skr894.80 Million | Skr354.40 Million | ▼ -7.4 pp |
| 2019 | 101.1% | Skr805.71 Million | Skr797.01 Million | Skr970.89 Million | Skr165.18 Million | ▼ -2.6 pp |
| 2018 | 103.7% | Skr327.48 Million | Skr315.83 Million | Skr441.32 Million | Skr113.84 Million | ▲ +3.9 pp |
| 2017 | 99.8% | Skr417.23 Million | Skr418.00 Million | Skr477.22 Million | Skr59.99 Million | ▲ +5.0 pp |
| 2016 | 94.8% | Skr24.97 Million | Skr26.34 Million | Skr54.27 Million | Skr29.30 Million | ▼ -11.8 pp |
| 2015 | 106.6% | Skr-2.77 Million | Skr-2.60 Million | Skr4.23 Million | Skr7.00 Million | ▲ +8.9 pp |
| 2014 | 97.7% | Skr7.43 Million | Skr7.61 Million | Skr12.94 Million | Skr5.52 Million | — |